

The banner features a dark blue background with a glowing DNA double helix and several purple virus-like particles. In the center, a pair of hands holds a glowing globe containing a family of three. The text 'InspiroGene™' is in white, with 'By McKesson' below it in a smaller font.

InspiroGene™

By McKesson

Bridging the gap between
CGT INNOVATION and REALITY

Regeneron Selects InspiroGene™ by McKesson as Distribution Partner for Otarmeni™ Gene Therapy

Collaboration supports the launch of a first-of-its-kind gene therapy for children and adults with genetic hearing loss

InspiroGene™ by McKesson, a dedicated business focused on supporting the commercialization of cell and gene therapies (CGTs), today announced it has been selected by Regeneron as a distribution partner for Otarmeni™ (lunsotogene parvec-cwaha), a first-in-class gene therapy approved by the FDA for the treatment of pediatric and adult patients with severe-to-profound and profound sensorineural hearing loss associated with molecularly confirmed biallelic variants in the *OTOF* (otoferlin) gene, preserved outer hair cell function, and no prior cochlear implant in the same ear. Through this collaboration, InspiroGene supports the distribution of Otarmeni to activated Authorized Treatment Centers across the United States as patient access expands.

Otarmeni aims to restore the biological pathway required for hearing by delivering a functional copy of the *OTOF* gene directly to the inner ear, offering new possibilities for patients and families affected by this life-altering form of hearing loss.

As Regeneron expands patient access to Otarmeni, InspiroGene is drawing on its established distribution infrastructure to help ensure the therapy reaches activated Authorized Treatment Centers across the United States. Leveraging its specialized cell and gene therapy storage and distribution capabilities, InspiroGene supports the secure handling, inventory management, and distribution of therapy to authorized sites of care.

"Otarmeni represents an important advancement for patients living with a rare genetic form of hearing loss," said Joe DePinto, Head of Cell, Gene and Advanced Therapies at McKesson. "Bringing cell and gene therapies to patients requires specialized capabilities across the supply chain, and we're helping manufacturers and treatment centers navigate that complexity to expand access to innovative treatments."

Otarmeni received multiple FDA designations during development, including Fast Track, Orphan Drug, Rare Pediatric Disease and Regenerative Medicine Advanced Therapy (RMAT), reflecting the significant unmet need within this patient population.